With hindsight: Full data challenge efficacy

Prescrire International

Volumn 12, Issue 67, 2003, Pages 168-171

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; AMITRIPTYLINE; ANALGESIC AGENT; CARBAMAZEPINE; GABAPENTIN; IMMUNOGLOBULIN G; LAMOTRIGINE; LIPID; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; PHENYTOIN; PLACEBO; ANTIBODY; ISOENZYME;

ANTIBODY PRODUCTION; ARTICLE; BIOCHEMISTRY; CELL LINE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFORMATION; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FABRY DISEASE; FOOD AND DRUG ADMINISTRATION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LIPID STORAGE; MEDICAL LITERATURE; NEUROPATHIC PAIN; PREDICTION; RISK ASSESSMENT; UNITED STATES; X CHROMOSOME LINKED DISORDER; COMPARATIVE STUDY; DRUG APPROVAL;

ALPHA-GALACTOSIDASE; ANTIBODIES; CLINICAL TRIALS; DRUG APPROVAL; FABRY DISEASE; HUMANS; ISOENZYMES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0642370818     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Prescrire Rédaction "agalsidase alfa - Replagal°, agalsidase bêta - Fabrazyme°: premier traitement substitutif pour la maladie de Fabry" Rev Prescr 2002; 22 (234): 817.
2. Schiffmann R et al. "Enzyme replacement therapy in Fabry disease. A randomized controlled trial" JAMA 2001; 285 (21): 2743-2749.
3. MacDermot K et al. "Enzyme replacement therapy reverses the cardiomyopathy of Fabry disease: results of a randomized, double-blind placebo controlled trial" 10th International congress of human genetics Vienna, May 15-19, 2001; abstr C074: 1 page.
4. Eng CM et al. "Safety and efficacy of recombinant human alphagalactosidase A replacement therapy in Fabry's disease" N Engl Med 2001; 345 (1): 9-16.
5. The European Agency for the Evaluation for Medicinal Products - Committee for Proprietary Medicinal Products - European Public Assessment Report "Replagal°" London 2001: 39 pages.
6. The European Agency for the Evaluation for Medicinal Products - Committee for Proprietary Medicinal Products - European Public Assessment Report "Fabrazyme°" London 2001: 42 pages.
7. Food and Drug Administration. Department of Health and Human Services - Division of Clinical Trial Design and Analysis "Agalsidase alfa - alphagalactosidase A for treatment of Fabry disease" 12 December 2002: 120 pages.
8. Food and Drug Administration. Department of Health and Human Services - Division of Clinical Trial Design and Analysis "Genzyme recombinant human alphagalactosidase for Fabry disease" 12 December 2002: 73 pages.
9. Genzyme "Fabrazyme° (agalsidase bêta) - Briefing document" (prepared for the meeting of 13 January 2003): 277 pages.
10. TKT "Replagal° (agalsidase alfa) - Briefing document" (prepared for the meeting of 14 January 2003): 129 pages.
11. Genzyme "Endocrinologic and metabolic drugs Advisory Committee meeting - Fabrazyme° (agalsidase bêta)" 13 January 2003: 16 pages.
12. TKT "Endocrinologic and metabolic drugs Advisory Committee meeting - Replagal BLA 103977" 14 January 2003: 15 pages.
13. United States of America - Food and Drug Administration - Center for drug evaluation and research "Endocrinologic and metabolic advisory committee meeting" 13 January 2003: 444 pages.
14. United States of America - Food and Drug Administration - Center for drug evaluation and research "Endocrinologic and metabolic advisory committee meeting" 14 January 2003: 394 pages.
15. Desnick RJ et al. "Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy" Ann Intern Med 2003; 138 (4): 338-346 (annex available at http://annals.org:1 page).
16. Lee K et al. "A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease" Glycobiology Advance Accro 2003: 35 pages.
17. Eng CM et al. "A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies" Am J Hum Genet 2001; 68: 711-722.
18. Branton MH et al. "Natural history of Fabry renal disease" Medicine 2002; 81 (2): 122-138.
19. Thurberg B et al. "Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy" Kidney Int 2002; 62: 1933-1946.